WO1987005608A1

WO1987005608A1 - Novel peptide derivatives

Info

Publication number: WO1987005608A1
Application number: PCT/SE1987/000141
Authority: WO
Inventors: Salo Arielly; Stig A^oke Ingemar GUSTAVSSON
Original assignee: Kabi Pharmacia AB
Current assignee: Pfizer Health AB
Priority date: 1986-03-21
Filing date: 1987-03-19
Publication date: 1987-09-24
Anticipated expiration: 1988-09-21
Also published as: EP0262191B1; JP2560058B2; SE8601327D0; JPS63502897A; FI875151A7; EP0262191A1; ATE70068T1; AU590836B2; FI875151L; FI875151A0; AU7169787A

Abstract

Tripeptide derivatives, characterized by general formula: R1 - X - D-Arg - A - Arg - NH - R2 wherein R1 is hydrogen, alpha- or beta-naphtyl residue, lower alkyl residue which may be substituted with a carboxyl group, unsubstituted or substituted phenyl- or phenylalkyl residue. X is (I), (II), (III) or a single bond with the proviso that when R1 is hydrogen then and only then X is a single bond; A = Gly or Sar; R2 = an aromatic or heterocyclic residue which gives a compound R2-NH2 by enzymatic hydrolysis, which can be determined quantitatively; or disalts and trisalts of inorganic or organic acids thereof, process for their preparation and method for determination of serine proteases, especially Factor Xa; or components which can interact with serine proteases or zymogen forms thereof.

Description

Novel Peptide Derivatives

Technical field

The present invention relates to novel tripeptide derivatives useful for determination of serine proteases. The novel derivatives are especially suitable for determination of Factor Xa_ (E.C.3.4.21.6) or for analyses of reactions, in which FXa_ is formed, inhibited or consumed which makes it possible to quantify other enzymes and/or inhibitors present in the reactions.

The background of the invention

Factor Xα_ is a key substance in the reaction cascade which leads to the blood coagulation. Several methods based on the determination of FX with chro ogenic substrate have shown to be of considerable value within the clinical diagnostic in explanation of disturbances in the blood coagulation system (Hemker H.C. - Handbook of synthetic substrates, 1983, Martinus Nijhoff Publishers, Boston).

Prior art

Chromogenic tetrapeptide derivatives are described by Aurell, L., et al. (Haemostasis vol. 7, 1978, 92-94) and have shown to be of considerable value in this case. These substrates are based on the a ino acid sequence (-Ile-Glu-Gly-Arg-) , which precedes the splitting places in the natural substrate prothrombin. The tetrapeptide substrates are characterized by high selectivity i.e. other enzymes, especially thrombin, do not disturb the determination of Factor X . Disadvantages are however the limited solubility and the several steps in the synthesis. EP 34 122 shows that tripeptide derivatives may be useful as FX_a substrates. However, these tripeptides are sensitive to thrombin too. The high selectivity of the tetrapeptides is not obtained by these tripeptides. Description of the invention

The tripeptide derivatives in the present invention show high sensitivity and solubility and simultaneously selectivity properties comparable with the tetrapeptides in the prior art. The novel substrates are characterized by the following formula:

₁ - X - D-Arg - A - Arg - NH - R₂

wherein R-, is hydrogen, - or β-naphtyl residue, lower alkyl residue which may be substituted with a carboxyl group, unsubstituted or substituted phenyl- or phenylalkyl residue, wherein the alkyl group having 1 to 4 carbon atoms and preferably wherein the substitution is in para position in the phenyl ring and the substituents are lower alkyl, lower alkoxy, halogen or nitro group;

lower alkyl is a straight or branched alkyl group having 1 to 4 carbon atoms, preferably methyl, ethyl or tert. butyl;

lower alkoxy is an alkoxy group having 1 to 4 carbon atoms, preferably methoxy;

halogen is chlorine, bromine, fluorine, or iodine, preferably chlorine:

0 0 0 II II II X = - 0 - C -, - C -, - S - or a single bond with the proviso that

0 when R, is a hydrogen then and only then X is a single bond

A = Gly or Sar

1*2 = an aromatic or heterocyclic residue which gives the compound 1*2 - NH« by enzymatic hydrolysis

or di- and tri-salts of inorganic or organic acids thereof.

These compounds R₂ - NH₂ are prior known compounds with chromogenic, fluorogenic or electrochemical properties which permit quantifying of serine proteases by determination of splitted marker directly or after derivatization (He ker H.C., loc. cit. and references cited therein).

Examples of compounds R₂ - H₂ are: p-nitroaniline, 3-carboxy-4-hydroxyaniline, 3-sulfo-4-nitroaniline, 3-alkoxy-4-nitroaniline, 3-carboxy-4-nitroaniline, 4-rnethoxy- -j_.-naphtylamine, 4-(N-ethyl-N--hydroxyethyl)aminoaniline, 5-amino-isophtalic acid-dimethyl ester, 5-amino-8-nitroquinoline, 7-amino-4-trifluoromethyl coumarine, 7-amino-4-methyl coumarine, 4-aminodiphenylamine.

The novel derivatives containing two amino acids with strong basic side-chain can form disalts or when R, is hydrogen trisalts with inorganic or organic acids. Preferred salts are disalts of inorganic or organic acids since they possess a high water solubility. Especially preferred salts are hydrochlorides.

The splitting of the substrates by the appropriate enzymes for determination takes place on the carboxylic side of arginine in L-form, therefore the N-terminal arginine must be as D-isomer. Surprisingly, at biological pH the negatively charged or neutral lipophilic part of the tetrapeptide substrate could be changed to a positively charged strong basic amino acid with retained high selectivity and increased sensitivity.

The use of the peptide derivatives according to the present invention in methods for quantitative and/or qualitative determination of serine proteases or quantitative and/or qualitative determination of components, which can interact with serine proteases or zymogen forms thereof, such as Factor X which is activated to Factor Xa., are important applications.

The novel Factor X_a substrates constitute by their sensitivity, high solubility and good selectivity a valuable addition at the establishment of diagnostic analyses based on determination of Factor X . A good a selectivity is an important critirion in determination of FXα_a in plasma, since there is otherwise a risk of influence from thrombin which may be^" present, initially or formed during the assay. Examples of important applications are determination of FX in human plasma, after activation with a protease from Russel's Viper Venom (RVV-X), of antifactor X_a, of heparin, and of FVIII.C at haemophilia (Hemker H.C., loc. cit., S. 5 Rosen, Scand. J. Haematol. Suppl. 40, vol. 33, 1984, 139-145). Especially important applications are analyses in connection with anticoagulantia treatment with low molecular weight heparin fractions, where traditional clot-based methods cannot be used. (Walenga J.M. et al., Seminars in Thrombosis and He ostatis, vol. 11, no. 2, 1985, 10 100-107). Specifically included are methods relying upon determination of FX -activity and used for the direct determination of FX and FX_fl or for the indirect determination of FVII, FVIIα_, FVIII.C, FVIII:C_, FIX,

FIXa,, antithrombin III, platelet factor 4, heparin, low molecular weight heparins and heparinoids. The properties of the novel substrates make 15 them especially suitable for use in automatic analysers.

Description of synthesis

At the synthesis of the novel FXα. substrates conventional protecting

20 groups and coupling methods within the peptide chemistry are used

(M. Bodansky: "Principles of Peptide Synthesis", Springer Verlag 1984), e.g. addition step-by-step of the amino acids at the C-terminal amino acid provided with a marker, or synthesis of the N-terminal peptide fragment per se, which then is coupled to the C-terminal amino acid

25. provided with a marker.

Useful amino protecting groups are benzyloxycarbonyl-, 9-fluorenyl- methyloxycarbonyl- or t-butyloxy-carbonyl groups. To protect the guanidino group of the arginine is used protonisation, a nitro- 30 protecting group or a p-toluenesulfonyl protecting group. The coupling between the amino acids are performed by activation of the c-carboxylic group (e.g. active esters, symmetric or asymmetric anhydrides, azide, DCCI or related reagents).

35 The invention will be described more in detail in the following not limited working examples, which show the preparation of different substrates according to the invention. Purification of the intermediates and end products is performed by precipitation, crystallization or gel filtration chromatography. The purified end products are lyophilized. Prefabricated glass plates of silica gel F₂₅₄ are used in the TLC analyses. After terminated chromatography the plates are inspected in UV light (254 nm) and are then developed with ninhydrin and chlorine/dicarboxidine reagent. The Revalues given are results from single chromatographies.

Solvent systems used for TLC are indicated according to the following table

Indication Solvent system Volume ratio

A = n-butanol: AcOH: water (3:2:1) Pa6 = chloroform: MeOH: AcOH: water (34:4:9:2)

M = n-butanol: AcOH: water: pyridine (15:3:12:10)

"3" = EtOAc: AcOH: water: pyridine (30:6:11:20)

HPLC analysis were performed on Merck RP column (Hibar LiChraCart) with 40% MeOH in 0.5% triethylaminophosphate pH = 2.35 as eluant (1 ml/min). The optical activity of the end products are determined at 589 nm in 50% acetic acid at a concentration of 0.4 - 1.0 g/100 ml and +25°C.

The below mentioned abbreviations have the following meaning: (IUPAC indication has been used where such exists).

Amino acids: Arg = arginine D-Arg = D-arginine Gly = glycine

Sar = sarcosine (N-methylglycine)

All amino acids in the substrates have L-configuration if nothing else is indicated.

The free amino acid or peptide is indicated by H- at the N-terminal amino group and -OH at the carboxyl terminal group. The amino group is always given to the left and the carboxyl group to the right. Abbreviations

Ac = acetyl

AcOH = acetic acid

AMC = 7-amino-4-methylcoumarine

Boc = t-butyloxycarbonyl

Bs = benzenesulfonyl

Bz = benzoyl

Bzls = benzylsulfonyl

CHA = 3-carboxy-4-hydroxyani1ide

4-ClBs = 4-chlorobenzenesulfonyl

DCCI = dicyclohexylcarbodiimide

DCU = dieyelohexylurea

DMF = dimethylformamide

Eoc = ethyloxycarbonyl

EtOAc = ethylacetate

EtOH = ethanol

Et₃N = triethylam ne

Ets = ethanesulfonyl

HOBT = 1-hydroxybenzotriazole

HPLC = High Performance Liquid Chromatograi

I = ionic strength

Mbs = 4-methoxybenzenesulfonyl

MeOH = methanol

Mes = methanesulfonyl

Moz = 4-methoxybenzyloxycarbonyl

4-Nbs = 4-nitrobenzenesulfonyl

NEM = 4-ethylmorpholine

4-Nz = 4-nitrobenzyloxycarbonyl

Ns = β-naphtalenesulfonyl

ONp = p-nitrophenylester pNA = p-nitroaniline

Sue = succinyl

TFA = trifluoroacetic acid

TLC = Thin Layer Chromatography

Tos = p-toluenesulfonyl

Tris = t is( ydroxymethyl)aminomethane

Z = benzyloxycarbonyl Working examples

Example 1

N°--Z-D-Arg-Gly-Arg-pNA'2 HC1 Molecular weight = 714.62

la) Boc-Gly-Arg-pNAΗBr Molecular weight = 532.40

43 mmol H-Arg-pNA-2HBr dissolved in 120 ml DMF is neutralized in cold

(-10°C) with Et₃N. The Et₃NΗBr formed is filtered off, whereafter 43 mmol Boc-Gly-OH, 45 mmol HOBT and 50 mmol DCCI are added. The reaction goes on during stirring for 1 hour in cold and at room temperature over the night. The DCU formed is filtered off and the solution is evaporated in vacuo to an oil which is dissolved in 160 ml EtOAc, is washed with 2% NaHC0₃, H₂0, 2% KHS0₄ and H₂0. After drying with Na₂S0» the EtOAc-phase is evaporated and precipated with diethylether. Yield: 71% TLC-: Rf = 0.23 (Pa₆).

lb) H-Gly-Arg-pNA«TFAΗBr Molecular weight = 546.36

55 ml TFA is added to 30 mmol Boc-Gly-Arg-pNA^«HBr (prepared according to Example la) dissolved in 55 ml methyleπechloride. The mixture is stirred for 30 minutes at room temperature and is precipated with diethylether thereafter. Yield: ~100%

TLC: Rf = 0.28 (A).

1. N^-Z-D-Arg-Gly-Arg-pNA^HCI Molecular weight = 714.62 2.5 mmol Z-D-Arg-OHΗCl, 3 mmol HOBT and 3 mmol DCCI are added to 2.5 mmol H-Gly-Arg-pNA-TFA-HBr (prepared according to Example lb) dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et₃N. The mixture is stirred for 1 hour in cold and for 48 hours at room temperature. The DCU formed is filtered off and the solution is evaporated in vacuo to an oil, 30 ml water is added and the solution is washed with 2x20 ml EtOAc. The water phase is evaporated in vacuo, the product is ion exchanged on a Sephadex^QAE-25 column, in chloride form with 50% EtOH as eluent and is purified on a Merck Lobar^prepacked column (LiChroprep^. RP-8-B) with 30% MeOH as eluent (2 l/min.) at the end. The purified product is lyophilized. Yield: 37% TLC: Rf = 0.11 (Pa₆) HPLC: 98.5% purity (&(] = -18.1° (c=0.5%)

Example 2

N -Boc-D-Arg-Gly-Arg-pNA^HCl Molecular weight = 680.59

2.5 mmol H-Gly-Arg-pNA-TFAΗBr and 2.5 mmol Boc-D-Arg-OH HCl are treated with the same coupling method and reaction conditions as in example 1. Yield: 35% TLC: Rf = 0.55 (M) HPLC: 96% purity jαj = -25.5° (c=0.4%) ^'

Example 3

H-D-Arg-Gly-Arg-pNA-3HC1 Molecular weight = 616.96

22 ml TFA is added to 12 mmol N^α-Boc-D-Arg-Gly-Arg-pNA-2HCl (prepared according to example 2) dissolved in 22 ml methylenechloride. The mixture is stirred for 30 minutes at room temperature and precipated with diethylether thereafter. The product is ion exchanged and purified in the same way as in example 1. Yield: 38% TLC: Rf = 0.30 (M) HPLC: 98% purity !«] = -62.4° (c=0.5%)

Example 4

Nfr-Ets-D-Arg-G1y-Arg-pNA.2HC1 Molecular weight = 672.62 0.5 mmol ethanesulfonylchloride and 80 μl Et₃N are added to 0.5 mmol H-D-Arg-Gly-Arg-pNA-3HCl (prepared according to example 3) dissolved in 10 ml DMF and neutralized in cold (-10°C) with 80 μl Et₃N. The reaction goes on during stirring for 1 hour in cold and for 2 hours at room temperature. The mixture is evaporated in vacuo. The product is ion exchanged and purified in the same way as in example 1. Yield: 44% TLC: Rf = 0.5 (M) HPLC: 97% purity

[«] = -15.6° (c=0.65%)

Example 5

N^-Bs-D-Arg-Gly-Arg-pNA^HCl Molecular weight * 720.66

0.5 mmol H-D-Arg-Gly-Arg-pNA«3HCl (prepared according to example 3) and

0.5 mmol benzenesulfonylchloride are treated in the same way and under the same reaction conditions as in example 4. Yield: 37% TLC: Rf = 0.53 (M) HPLC: 98% purity [<*] = +11.6° (c=0.45%)

Example 6

N^<*-4-Nz-D-Arg-Gly-Arg-pNA»2HCl Molecular weight = 759.64 0.5 m ol H-D-Arg-Gly-Arg-pNA-3HCl (prepared according to example 3) and 0.5 mmol 4-nitrobenzyloxycarbonylchloride are treated in the same way and under the same reaction conditions as in example 4. Yield: 57%

TLC: Rf = 0.3 (A)

HPLC: 99% purity

[pQ = -20.2°C (c=0.45%)

Example 7

N*-4-Nbs-D-Arg-Gly-Arg-pNA^»2HCl Molecular weight = 765.66 0.5 mmol H-D-Arg-Gly-Arg-pNA^»3HCl (prepared according to example 3) and 0.5 mmol 4-nitrobenzenesulfonylchloride are treated in the same way and under the same reaction conditions as in example 4. Yield: 25% TLC: Rf = 0.28 (A) HPLC: 97% purity ]VJ = -0.8° (c=0.6%)

Example 8

N^K-Tos-D-Arg-Gly-Arg-pNA•2HC1 Molecular weight = 734.69 0.5 mmol H-D-Arg-Gly-Arg-pNA-3HCl (prepared according to example 3) and 0.5 mmol p-toluenesulfonylchloride are treated in the same way and under the same reaction conditions as in example 4. Yield: 45%

TLC: Rf = 0.25 (A)

HPLC: 98% purity

[⁽] = +23.1° (c=0.45%)

Example 9

N^-Moz-D-Arg-Gly-Arg-pNA'2HCl Molecular weight = 744.66 0.5 mmol H-D-Arg-Gly-Arg-pNA»3HCl (prepared according to example 3) and 0.5 mmol 4-methyloxybenzyloxycarbonylazide are treated in the same way and under the same reaction conditions as in example 4. Yield: 31% TLC: Rf = 0.22 (A) HPLC: 97% purity [ex] = -15.9° (c=0.4%)

Example 10

Ntt-Mbs-D-Arg-Gly-Arg-pNA^»2HCl Molecular weight = 750.69

0.5 mmol H-D-Arg-Gly-Arg-pNA-3HCl (prepared according to example 3) and 0.5 mmol 4-methoxybenzenesulfonylchloride are treated in the same way and under the same reaction conditions as in example 4.

Yield: 45%

TLC: Rf = 0.31 (A)

HPLC : 99% purity [a] = +22.8° (c=0.4%) Example 1 1

N^α-4-ClBs-D-Arg-Gly-Arg-pNA'2HCl Molecular weight = 755.12 0.5 mmol H-D-Arg-Gly-Arg-pNA^*3HCl (prepared according to example 3) and 0.5 mmol 4-chlorobenzenesulfonylchloride are treated in the same way and under the same reaction conditions as in example 4. Yield: 31% TLC: Rf = 0.38 (A) HPLC: 99% purity [0] = +10.9° (c=0.4%)

Example 12

N^-Ns-D-Arg-Gly-Arg-pNA^»2HCl Molecular weight = 770.73 0.5 mmol H-D-Arg-Gly-Arg-pNA^«3HCl (prepared according to example 3) and

0.5 mmol J3-naphtalenesulfonylchloride are treated in the same way and under the same reaction conditions as in example 4.

Yield: 25%

TLC: Rf = 0.29 (A) HPLC: 99% purity

[O] = -21.5° (c=0.4%)

Example 13

N^-Z-D-Arg-Gly-Arg-AMC-2HC1 Molecular weight ? 751.70

2 mmol Z-D-Arg-Gly-OH-HCl, 2.5 mmol HOBT and 2.5 mmol DCCI are added to 2 mmol H-Arg-AMC* 2HC1 dissolved in 30 ml DMF and neutralized in cold (-10°C) with Et₃N. The reaction is performed during stirring for 1 hour in cold and for 24 hours at room temperature. The DCU formed is filtered off and the solution is evaporated in vacuo to an oil, which is ion exchanged and purified in the same way as in example 1. Yield: 39% TLC: Rf = 0.7 ("3") HPLC: 99% purity = -28.6° (c=0.5%) Example 14

N^-Ac-D-Arg-Gly-Arg-pNA-2HC1 Molecular weight = 622.54 0.5 mmol H-D-Arg-Gly-Arg-pNA«3HCl (prepared according to example 3) and 0.5 mmol acetic acid anhydride are treated in the same way and under the same reaction conditions as in example 4. Yield: 43% TLC: Rf = 0.45 (M) HPLC: 97% purity M = -27.9° (c=0.4%)

Example 15

N^-Suc-D-Arg-Gly-Arg-pNA-2HC1 Molecular weight = 680.57 0.5 mmol H-D-Arg-Gly-Arg-pNA»3HCl (prepared according to example 3) and

0.5 mmol succinic acid anhydride are treated in the same way and under the same reaction conditions as in example 4.

Yield: 40%^'

TLC: Rf = 0.23 (A) HPLC: 98% purity

[Of] = -21.4° (c=0.5%)

Example 16

N°^*-Bzls-D-Arg-Gly-Arg-pNA-2HCl _. Molecular weight 734.69

0.5 mmol H-D-Arg-Gly-Arg-pNA*3HCl (prepared according to example 3) and 0.5 mmol benzylsulfonylchloride are treated in the same way and under the same reaction conditions as in example 4. Yield: 38% TLC: Rf = 0.26 (A) HPLC: 98% purity [«] = -7.8 (c=0.4%) Example 17

N^<-Bz-D-Arg-Gly-Arg-pNA-2HCl Molecular weight = 684.61

17a) Z-Gly-Arg(N0₂)-pNA Molecular weight = 530.51

0.35 mol H-Arg-(NO pNA'HBr dissolved in 750 ml DMF is neutralized in cold (-10°C) with Et₃N. The Et₃N*HBr formed is filtered off, whereafter 0.35 mol Z-Gly-OH, 0.35 mol HOBT and 0.38 mol DCCI are added. The reaction is performed during stirring for 1 hour in cold and at room temperature over the night. The DCU formed is filtered off and the solution is evaporated in vacuo to an oil, which is triturated with 3x400 ml 2% NaHC0₃ and 500 ml water. The product is recrystallized from 3.5 1 MeOH. Yield: 80% TLC: Rf = 0.6 (Pa₆)

17b) H-Gly-Arg(N0₂)-pNA-HC1 Molecular weight = 432.72 0.3 mol Z-Gly-Arg(N0₂)-pNA (prepared according to example 17a) is suspended in 630 ml AcOH. 415 ml 5.6 M HBr in AcOH is added during stirring. The mixture is stirred for 45 minutes at room temperature and poured into 7.5 1 dry diethylether during stirring. The precipitate is filtered, washed with diethylether and dried in vacuo. Yield: 90%

3 g product is ion exchanged in the same way as in example 1. Yield: 73%

TLC: Rf = 0.15 (Pa₆).

17c) N^CT-Boc-D-Arg(N0₂)-Gly-Arg(NQ₂)-pNA Molecular weight = 697.69

4 mmol H-G1y-Arg(N0₂)-pNA^«HCl (prepared according to example 17b) dissolved in 25 ml DMF is neutralized in cold (-10°C) with EtgN. The EtgNΗCl formed is filtered off, whereafter 4 mmol #-Boc-D-Arg(N0₂)-OH, 4 mmol HOBT and 4.2 mmol DCCI are added. The reaction is performed during stirring for 1 hour in cold and at room temperature over the night. The DCU formed is filtered off and the solution is evaporated in vacuo to an oil, which is suspended with 2% NaHC0₃, water, 2% KHS0₄, water and diethylether. Yield: 73% TLC: Rf = 0.32 (Pa_g) 17d) H-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA»HCl Molecular weight = 634.04 3 mmol N^-Boc-D-Arg-(N0₂)-Gly-Arg(N0₂)-pNA (prepared according to example 17c) is suspended in 11 ml AcOH, 11 ml TFA is added and the mixture is stirred for 4 hours at room temperature. The product is precipitated with diehtylether and ion exchanged in the same way as in example 1. Yield: 72% TLC: Rf = 0.61 (M)

17e) N^-Bz-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA Molecular weight = 701.68 0.6 mmol benzoic anhydride and 70 μl Et₃N are added to 0.5 mmol H-D-Arg(N0₂)-Gly-Arg(N0,-)-DNAΗCl (prepared according to example 17d) dissolved in 20 ml DMF and neutralized in cold (-10°C) with 70 μl Et₃N. The reaction is performed during stirring for 1 hour in cold and for 2 hours at room temperature. The mixture is evaporated in vacuo and precipitated with water. The product is suspended with 30 ml warm MeOH, is filtrated and dried.

Yield: 68%

TLC: Rf = 0.31 (Pa₆)

17. N^or-Bz-D-Arq-Glv-Arq-pNA 2HC1 Molecular weight = 684.61 0.35 mmol N^O-Bz-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA (prepared according example 17e) is deprotected by reaction with 15 ml dry HF in presence of 0.5 ml anisole in a suitable apparatus according to Sakakibara (S. Sakakibara et al. Bull. Chem. Soc, Japan vol. 240 p. 7164-67, 1967) for 60 minutes at 0°C. After terminated reaction all HF is distilled and the raw product is ion exchanged and purified in the same way as in example 1. Yield: 36% TLC: Rf = 0.55 (M) HPLC: 98% purity

U = -24.4° (c=0.6%) Example 18

N«-Eoc-D-Arg-Gly-Arg-pNA^»2HC1 Molecular weight = 652.57

18a) N^όf-Eoc-D-Arg(N0₂)-Gly-Arg(NQ₂)-pNA Molecular weight = 669.63 0.6 mmol ethylchloroformate and 70 μl Et₃N are added to 0.5 mmol H-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA-HCl (prepared according to example 17d) dissolved in 20 ml DMF and neutralized in cold (-10°C) with 70 μl EtgN. The reaction goes on during stirring for 1 hour in cold and for 2 hours at room temperature. The mixture is evaporated in vacuo and precipitated with water, filtrated and washed with water and diethylether. Yield: 89% TLC: Rf = 0.26 (Pa_g)

18. N -Eoc-D-Arg-Gly-Arg-pNA-2HC1 Molecular weight = 652.57 0.45 mmol N^Λ-Eoc-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA (prepared according to example 18a) is deprotected by reaction with 20 ml dry HF in presence of 0.5 ml anisole in the same way as in example 17. Yield: 41% TLC: Rf = 0.55 (M) HPLC: 98% purity [*] = -25.2° (c=0.35%)

Example 19

N^ft-Mes-D-Arg-Gly-Arg-pNA'2HCl Molecular weight = 658.60

19a) N^-Mes-D-Arg(N0₂)-Gly-Arg( 0₂)-pNA Molecular weight = 675.66

0.5 mmol H-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA*HCl (prepared according to example 17d) dissolved in 20 ml DMF and 0.6 mmol methanesulfonylchloride are treated in the same way and under the same reaction conditions as in example 17e.

Yield: 70%

TLC: Rf = 0.47 (A) 19. N^-Mes-D-Arg-G1y-Arg-pNA-2HC1 Molecular weight = 658.60 0.35 m ol N^Q Mes-D-Arg(N0₂)-Gly-Arg(N0₂)-pNA (prepared according to example 19a) is deprotected and purified in the same way as in example 17. Yield: 43.5%

TLC: Rf = 0.48 (M)

HPLC: 97% purity

[α] = -17.6° (c=0.5%)

Example 20

N^a-Z-D-Arg-Sar-Arg-pNA'2HCl Molecular weight = 728.66

20a) H-Sar-Arg-pNA-2HCl Molecular weight = 438.33 5 mmol Boc-SarOH, 5 mmol HOBT and 6 mmol DCCI are added to 5 mmol

H-Arg-pNA-2HCl dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et₃N. The mixture is stirred for 1 hour in cold and at room temperature over the night. The DCU formed is filtered off and the solution is evaporated in vacuo to an oil, which is dissolved in 100 ml n-butanol, washed with 2% NaHC0₃, H₂0, 2% KHS0₄ and H₂0. After drying with a₂S0,, the n-butanol phase is evaporated and precipitated with diethylether. The precipitate is filtrated, washed with diethylether and dried. The substance is suspended in 25 ml HCl-solution (1.5 M in AcOH) and stirred for 2 hours at room temperature, precipitated with diethyl- ether and ion exchanged in the same way as in example 1. Yield: 63.5% TLC: Rf = 0.15 (A)

20. N^tf-Z-D-Arg-Sar-Arg-pNA'2HC1 Molecular weight = 728.66 3 mmol Z-D-ArgOHΗCl, 3 mmol HOBT and 3.5 mmol DCCI are added to 3 mmol Sar-Arg-pNA^»2HCl (prepared according to example 20a) dissolved in 30 ml DMF and neutralized in cold (-10°C) with Et₃N. The mixture is stirred for 1 hour in cold and for 72 hours at room temperature. The DCU formed is filtered off and the solution is evaporated in vacuo. The product is ion exchanged and purified in the same way as in example 1. Yield: 43% TLC: Rf = 0.2 (A) HPLC: 99% purity

[Of] = -24.7° (c=0.55%)

Example 21

N^-Z-D-Arg-Gly-Arg-CHA^HCl Molecular weight = 729.65

21a) Boc-Arg-CHAΗCl

3.2 mmol isobutyl chloroformate is added to 3.0 mmol Boc-Arg-CHA-HCl dissolved in 10 ml DMF and neutralized in cold (-10°C). The reaction mixture is stirred for 15 minutes in cold and a mixture of 3 mmol 3-carboxy-4-hydroxianiline, 3 mmol NEM and 10 ml DMF are added. The reaction goes on under stirring for 2 hours in cold and at room temperature over the night. The solution is evaporated in vacuo to an oil. 50 ml n-butanol is added and the mixture is stirred for 3 hours at room temperature. The Boc-Arg-CHAΗCl formed is filtered off. Yield: 50% TLC: Rf = 0.5 (A)

21b) H-Arg-CHA_'HCl Molecular weight = 382.25

8 ml 2N HCl in AcOH is added to 2 mmol Boc-Gly-Arg-CHA*HCl . The reaction goes on for 45 minutes at room temperature. The reaction mixture is evaporated in vacuo to an oil, which is dissolved in isopropanol and precipitated with EtOAc. Yield: 97%

TLC: Rf = 0.15 (A)

21c) Boc-Gly-Arg-CHA-HCl Molecular weight = 502.95

2 mmol H-Arg-CHA-2HC1 dissolved in 12 ml DMF is neutralized in cold (-10°C) with NEM, whereafter 2.1 mmol Boc-Gly-ONp is added. The reaction goes on under stirring for 1 hour in cold and at room temperature over the night. The solution is evaporated in vacuo to an oil which is dissolved in 10 ml MeOH and precipitated with EtOAc. Yield: 88% TLC: Rf = 0.4 (A) 21d) H-Gly-Arg-CHA-2HC1 Molecular weight = 439.30

10 ml 2N HCl in AcOH is added to 2 mmol Boc-Gly-Arg-CHA HCl. The reaction mixture is stirred for 45 minutes at room temperature and then precipitated in EtOAc. Yield 98%

TLC: Rf = 0.15 (A)

21. N^K-Z-D-Arg-Gly-Arg-CHA^»2HC1 Molecular weight = 729.65

1 mmol H-Gly-Arg-CHA-2HC1 dissolved in 10 ml DMF is neutralized in cold (-10°C) with NEM, whereafter 1.1 mmol Z-D-Arg-0Np^«HN0₃ is added. The reaction goes on for 1 hour in cold and for 2 hours at room temperature.

form with 50% EtOH as eluent.

Yield: 57%

TLC: Rf = 0.21 (A)

HPLC : 99% purity

[x] = - 18.6° ( C = 0.3%)

Experiments

Determination of enzyme kinetic properties

The kinetic data for the substrates are determined by measuring the initial velocity of hydrolysis (Vi) at different substrate concentrations (Si) and at constant enzyme concentrations (Eo). The binding constant (Km) and the maximum velocity (Vm__ax) are obtained in known manner from Lineweaver-Burk-plot, then the K . is calculated (Hemker H.C. loc. cit.).

Methods

Enzymes and substrates are mixed in a buffer solution at +37°C. The absorbance change per minute is measured at 405 nm in a spectrophoto- meter (pNA-substrate) or in a spectrofluorometer at excitation wavelength 380 nm and emission wavelength 440 nm (AMC-substrate) . The following commercially available reference substrates are used in the tests:

Reference substrates

S-2222: Bz-Ile-Glu-(^-0R)-G1y-Arg-pNA-HCl

R: H=50%; CH₃=50%.

KabiVitrum AB, Stockholm, Sweden.

CBS 31.39: CH₃S0₂-D-Leu-Gly-Arg-pNA-Ac0H

Diagnostica Stago, Asnieres s/Seine, France.

Tes,t 1_. Determination of the kinetic constants for FXd, bovine

FXα, bovine (KabiVitrum) with a constant enzyme concentration

Eg = 4 nmol/1 (pNA - substrate) E_Q = 2 nmol/1 (AMC - substrate) and the substrate in concentrations between 0.01 - 0.4 mmol/1 (Si) are mixed in a trisbuffer solution 0.05 mol/1, pH = 8.3, I = 0.25 (NaCl) at

37°C. Absorbance change per minute is measured at 405 nm in a spectrophotometer for pNA - substrate and in a spectrofluorometer at emission wavelength 440 nm for AMC-substrate, respectively. From these values then m, and I cat. are calculated, which are shown in table I.

Table I shows that the tripeptide substrates according to the invention possess a high affinity to the enzyme FXa, bovine simultaneously as most of the substrates have a high rate of velocity. The selectivity constant ./ states that the new substrates show a better selectivity for FXα, bovine than S-2222 and that even most of the new substrates are superior to CBS 31.39.

Test 2. Determination of kinetic constants for FX, human

The substrates in concentrations between 0.1 - 0.7 mmol/1 (Si) are mixed with FX human plasma and treated according to the method as described by Aurell; L., et al. (Perspectives in Hemostatis, Ed. Fareed J. et al, New York, Pergamon Press 1981, p. 382-388).

10 μl test plasma, control or standard and 200 μl trisbuffer solution (0.05 mol/1 tris, pH 7.0, I = 0.25 (NaCl)), polybrene (0.1 g/1) are mixed and incubated at 37°C for 2-4 minutes. 200 μl substrate (37°C) in concentrations between 0.1 - 0.7 mmol/1 dissolved in trisbuffer solution prepared according to the above are added. The mixture is well stirred and within 30 seconds 200 μl RVV+CaCl₂ (20-25°C) are added and the mixture is stirred. The absorbance change is measured at once in a spectrophotometer at 405 nm and 37°C.

The results are shown in table II. Table II shows that the new tripeptide substrates possess a superior affinity for enzyme FXα, human compared with the reference substrates simultaneously as they also show a high rate of velocity, which makes them superior to the commercial available substrates.

Test 3. Determination of thrombin sensitivity

At the determination of FX in plasma there is always a risk for formation of active thrombin which disturbes the FXα, determination.

Thrombin bovine (KabiVitrum) with a constant concentration

EQ = 1.3 nmol/1 and the substrates in concentrations between

0.1 - 0.4 mmol/1 (Si) are mixed in a trisbuffer solution (0.05 mol/1, pH = 8.3, I = 0.25 (NaCl)) at 37°C. The test is performed according to test 1.

The absorbance change per minute is measured at 405 nm in a spectrophotometer and the K are calculated as showed in

table III.

Table III shows that the ratio for the selectivity ^J constant FXa, bovine through thrombin for the new tripeptide substrates can be compared with the tetrapeptide and are superior to the known tripeptide when the sensitivity for FXα, bovine is compared to thrombin.

Test 4. Solubility

The solubility in water and trisbuffer solution (0.05 mol/1, pH = 8.3, I = 0.25 (NaCl)), respectively at 25°C for some new substrates are shown in table IV compared with the tetrapeptide substrate S-2222.

The table shows that the new tripeptide substrates have a clearly higher solubility in water as well as in buffer solution compared with the tetrapeptide S-2222. Table I

Table II

Tabell III

Claims

1. Tripeptide derivatives, characterized by the general formula:

R₁ - X - D-Arg - A - Arg - NH - R₂

wherein R, is hydrogen, #- or β-naphtyl residue, lower alkyl residue which may be substituted with a carboxyl group, unsubstituted or substituted phenyl- or phenylalkyl residue, wherein the alkyl group having 1 to 4 carbon atoms and preferably wherein the substitution is in para position in the phenyl ring and substituted with a lower alkyl, lower alkoxy, halogen or nitro group.

0 0 0 II II II X = - 0 - C -, - C -, - S - or a single bond with the proviso that when

0

R is hydrogen then and only then X is a single bond

A = Gly or Sar

R« = an aromatic or heterocyclic residue which gives a compound Rp-NH_^ by enzymatic hydrolysis, which can be determined quantitatively

or disalts and trisalts of inorganic or organic acids thereof.

2. Tripeptide derivatives according to claim 1 characterized by that A is Gly.

3. Tripeptide derivatives according to any of claims 1-2 characterized by that X is a oxycarbonyl- or sulfonyl group.

4. Tripeptide derivatives according to any of claims 1-3 characterized by that NH₂~R₂ is a chromogenic or a fluorogenic group.

5. Tripeptide derivatives according to claim 4 characterized by that NH₂-R₂ is pNA, AMC or CHA.

6. Tripeptide derivatives according to any of claims 1-5 characterized by that R, is ethyl, benzyl or tert.butyl.

7. Tripeptide derivative according to any of claims 1-6 in form of disalts.

8. Tripeptide derivative according to claim 1 which is N^Λ-Bzls-D-Arg- -Gly-Arg-pNA-2HCl.

9. Tripeptide derivative according to claim 1 which is N*-Mos-D-Arg- -Gly-Arg-pNA-2HCl.

10. Tripeptide derivative according to claim 1 which is N*-Ets-D-Arg- -Gly-Arg-pNA-2HCl.

11. Tripeptide derivative according to claim 1 which is N°--Z-D-Arg- -Gly-Arg-pNA-2HCl.

12. Tripeptide derivative according to claim 1 which is N#-Boc-D-Arg- -Gly-Arg-pNA-2HCl.

13. Process for preparation of tripeptide derivatives according to any of claims 1-12 characterized in that the synthesis is performed step-by-step by coupling to Arg which have -NH-R₂ or a deprotectable carboxyl protecting group which then is exchanged by -NH-R-,, or by coupling of R,-X-D-Arg-A to Arg-NH-R₂.

14. Method for determination of serine proteases, especially Factor X , characterized by the use of peptide derivatives according to any of claims 1-12.

15. Method for determination of components which can interact with serine proteases or zy ogen forms thereof characterized by the use of peptide derivatives according to any of claims 1-12.

16. Method according to claims 14 or 15 for determination of FX, FVII,

FVIIa, FVIII:C, FVIII:Ca, FIX, FIXa. antithrombin III, platelet factor

4, heparin, low molecular weight heparins and heparinoids.